The Primary CNS Lymphoma drugs in development market research report provides comprehensive information on the therapeutics under development for Primary CNS Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary CNS Lymphoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary CNS Lymphoma and features dormant and discontinued products.
GlobalData tracks 38 drugs in development for Primary CNS Lymphoma by 33 companies/universities/institutes. The top development phase for Primary CNS Lymphoma is phase ii with 23 drugs in that stage. The Primary CNS Lymphoma pipeline has 36 drugs in development by companies and two by universities/ institutes. Some of the companies in the Primary CNS Lymphoma pipeline products market are: Bristol-Myers Squibb, Nurix Therapeutics and Iovance Biotherapeutics.
The key targets in the Primary CNS Lymphoma pipeline products market include B Lymphocyte Antigen CD19, Tyrosine Protein Kinase BTK, and Protein Cereblon.
The key mechanisms of action in the Primary CNS Lymphoma pipeline product include Tyrosine Protein Kinase BTK Inhibitor with ten drugs in Phase II. The Primary CNS Lymphoma pipeline products include 13 routes of administration with the top ROA being Intravenous and five key molecule types in the Primary CNS Lymphoma pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Primary CNS Lymphoma overview
Primary CNS lymphoma (PCNSL) is a rare extranodal lymphoma that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without evidence of systemic involvement. It is a subtype on, and one of the most aggressive forms of, diffuse large B-cell lymphoma. PCNSL is more common in immunosuppressed patients, such as those with HIV/AIDS or transplant recipients, and is often associated with Epstein-Barr virus infection. PCNSL usually presents with neurological symptoms such as headache, seizure, cranial nerve deficits, or altered mental status, depending on the location and size of the tumor. The diagnosis of PCNSL requires histopathological confirmation from CSF cytology, vitreous biopsy, or brain/leptomeningeal biopsy. MRI or contrast-enhanced CT typically shows multiple ring-enhancing lesions in the deep white matter. The treatment of PCNSL consists of high-dose methotrexate-based chemotherapy, followed by consolidation with radiation, maintenance therapy, or stem cell transplant. The prognosis of PCNSL is poor, with a 5-year survival rate of 30-40%.
For a complete picture of Primary CNS Lymphoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
